arrow
R

Robert D. Morgan

University of Manchester
H指数:28
被引数:2,649

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK

西地尼布联合每周多西他赛或奥拉帕利与每周多西他赛对比治疗晚期或复发性子宫内膜癌(COPELIA):一项在英国进行的多中心、开放标签、随机、II期临床试验

2026-06-010
OAAI
Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis

携带NBN基因致病性或可能致病性变异的女性罹患卵巢癌的风险:一项系统评价和荟萃分析

2026-02-160
OAAI
Overall survival for bevacizumab therapy in metastatic colorectal cancer: an updated analysis of the TRAVASTIN study

贝伐珠单抗疗法在转移性结直肠癌中的总生存期:TRAVASTIN研究的更新分析

2025-11-120
PRE
The Incidence Of Breast Cancer In Ovarian Cancer Patients With BRCA Mutations: A Multicentre Retrospective Cohort Study.

BRCA突变卵巢癌患者中乳腺癌的发病率:一项多中心回顾性队列研究。

2025-02-010
PRE
Association between chemotherapy response score (CRS) and tumour homologous recombination deficiency (tHRD) in women with newly diagnosed FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)

新诊断为FIGO分期IIIC/IV期的高级别浆液性卵巢癌(HGSOC)女性患者中,化疗反应评分(CRS)与肿瘤同源重组缺陷(tHRD)之间的关联。

2024-09-010
PRE
Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary

对未经筛选的、新诊断为高级别浆液性卵巢癌(HGSOC)的女性进行错配修复(MMR)基因的胚系致病变异(PVs)检测是不必要的。

2024-09-010
PRE
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2023-02-178
OA